Powers Advisory Group’s AbbVie ABBV Stock Holding History

Powers Advisory Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$304K	Buy	1,206 +22	+2%	+$4.73K	0.1%	108
2026 Q1	$257K	Sell	1,184 -46	-4%	-$10.2K	0.09%	112
2025 Q4	$281K	Buy	1,230 +19	+2%	+$4.33K	0.11%	106
2025 Q3	$280K	Buy	+1,211	New	+$247K	0.11%	101

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Powers Advisory Group's ABBV Position: Q2 2026 in Review

Powers Advisory Group increased its AbbVie (ABBV) stake by 1.9% in Q2 2026, buying an estimated $4.73K and bringing the position to 1,206 shares worth $304K. The position accounts for 0.1% of the portfolio, ranked #108.

Powers Advisory Group first reported a position in ABBV in Q3 2025 and has held it in 4 quarters since. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Powers Advisory Group held 1,206 shares of AbbVie worth $304K as of Q2 2026.
Powers Advisory Group bought 22 AbbVie shares in Q2 2026, an estimated $4.73K.
AbbVie made up 0.1% of Powers Advisory Group's portfolio in Q2 2026, its #108 holding.
Powers Advisory Group first reported a position in AbbVie in Q3 2025 and has held it in 4 quarters since.
4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Powers Advisory Group's 13F filing for Q2 2026, filed 31 Jul 2026.